Press Release

Genomics in Cancer Care Market to Grow with a CAGR of 16.91% through 2030

Advancements in next-generation sequencing (NGS) technology and increasing adoption of precision medicine, is expected to drive the Global Genomics in Cancer Care Market growth in the forecast period, 2026-2030

 

According to TechSci Research report, “Genomics in Cancer Care Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Genomics in Cancer Care Market stood at USD 15.73 Billion in 2024 and is expected to reach USD 40.22 Billion by 2030 with a CAGR of 16.91% during the forecast period. The Global Genomics in Cancer Care Market is undergoing rapid transformation driven by continuous innovation in molecular diagnostics and targeted therapies. The increasing emphasis on tumor profiling and genetic sequencing has enabled oncologists to develop personalized treatment plans, improving patient survival rates. Research advancements in circulating tumor DNA (ctDNA) analysis and single-cell sequencing are revolutionizing early detection and treatment monitoring. The expanding role of big data and cloud computing in genomic research is streamlining data storage, analysis, and sharing, accelerating the pace of discoveries in oncology care.

Key growth drivers include the surge in clinical trials exploring gene-based therapies, rising demand for pharmacogenomics, and the increasing role of public-private partnerships in cancer genomics research. The expansion of multi-cancer early detection (MCED) tests is broadening the scope of genomic applications in oncology. Improvements in sequencing accuracy and turnaround time are making genomic testing more accessible to healthcare providers. The growing availability of direct-to-consumer genetic tests is fostering patient awareness and encouraging proactive cancer risk assessment. Collaborations between biotech firms and healthcare institutions are driving the commercialization of advanced genomic solutions, contributing to the market's upward trajectory.

The market presents several growth opportunities, including the rise of CRISPR-based gene editing in cancer therapeutics and the exploration of novel genomic biomarkers for rare cancers. The expansion of liquid biopsy applications beyond detection to treatment response prediction is unlocking new commercial prospects. Advancements in nanopore sequencing and single-molecule analysis are expected to further refine genomic insights, improving precision oncology approaches. The increasing integration of genomics with immunotherapy is paving the way for highly personalized cancer treatments. Strategic investments in AI-powered genomic analytics and cloud-based bioinformatics platforms will drive the next phase of innovation, solidifying genomics as a cornerstone of cancer care.

           

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Genomics in Cancer Care Market

 

The Global Genomics in Cancer Care Market is segmented into product, technology, application, end user, regional distribution, and company.

Based on the Application, Personalized Medicine emerged as the fastest growing segment in the Global Genomics in Cancer Care Market during the forecast period. This is due to the increasing shift toward targeted therapies and precision oncology. Advances in genomic technologies have enabled the identification of specific genetic mutations and biomarkers that drive cancer progression, allowing for the development of tailored treatment approaches. The growing adoption of next-generation sequencing (NGS) and companion diagnostics has revolutionized cancer care by enabling oncologists to prescribe therapies based on an individual’s genetic profile, improving treatment efficacy and minimizing adverse effects. The rising prevalence of cancer and the demand for more effective and less toxic treatment options have further accelerated the adoption of personalized medicine. Pharmaceutical companies are investing heavily in biomarker-driven drug development, leading to a surge in regulatory approvals for targeted therapies. The integration of artificial intelligence (AI) and bioinformatics in genomic analysis is enhancing precision medicine by streamlining data interpretation and facilitating real-time decision-making in oncology.

Based on the Region, Asia-Pacific emerged as the fastest growing region in the Global Genomics in Cancer Care Market during the forecast period. This is due to increasing investments in precision medicine, expanding healthcare infrastructure, and rising cancer prevalence. Governments across countries such as China, Japan, and India are actively promoting genomic research and implementing national initiatives to integrate genomics into oncology care. Significant funding from public and private sectors for next-generation sequencing (NGS) technologies, biomarker discovery, and personalized medicine programs is accelerating market growth. The region’s large patient population and improving accessibility to advanced genomic testing are further driving demand for genomics-based cancer diagnostics and treatment. Rapid advancements in biotechnology, coupled with a surge in pharmaceutical and biotech collaborations, are facilitating the development of targeted therapies. The increasing adoption of liquid biopsy and companion diagnostics, particularly in countries with strong regulatory support like Japan and South Korea, is enhancing early cancer detection and treatment monitoring. Additionally, declining sequencing costs and the expansion of local genomic service providers are making precision oncology more affordable and widely available. The growing presence of international genomics companies and strategic partnerships with regional healthcare institutions are strengthening Asia-Pacific’s position as a key driver of growth in the global genomics in cancer care market.

 

Major companies operating in Global Genomics in Cancer Care Market are:

  • Illumina Inc
  • Agilent Technologies, Inc.
  • Roche Diagnostics
  • Cancer Genetics, Inc.
  • Bio-Rad Laboratories Inc
  • Sigma-Aldrich Corp
  • QIAGEN NV
  • GE Healthcare Inc
  • Life Technologies Corp
  • Quest Diagnostics Inc

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Global Genomics in Cancer Care Market is expanding due to the growing adoption of multi-omics approaches, including genomics, transcriptomics, and proteomics, which are revolutionizing cancer diagnostics and treatment. By integrating data from multiple molecular layers, researchers and clinicians can gain deeper insights into tumor biology, leading to more precise patient stratification and targeted therapy development. This comprehensive approach enhances the accuracy of biomarker identification, improves treatment response predictions, and accelerates drug discovery. The increasing use of artificial intelligence and bioinformatics in multi-omics data analysis is further driving advancements in precision oncology.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

Genomics in Cancer Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables, Services), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By End User (Hospitals, Research Institutes & Academic Institutes, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Genomics in Cancer Care Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Genomics in Cancer Care Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com

Relevant News